Michelle Renee Griffin Sells Shares of Adaptive Biotechnologies

On June 25, 2026, Michelle Renee Griffin sold 52,084 shares of Adaptive Biotechnologies Corporation (NasdaqGS: ADPT). The transaction was not planned, and it involved a non-market price.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

Griffin's recent sale was part of several insider transactions at Adaptive Biotechnologies. On the same day, Susan Bobulsky, the Chief Commercial Officer for MRD, sold 5,000 shares at $20.50 in a planned transaction. Additionally, Harlan Robins, the Chief Scientific Officer, sold 6,160 shares at $18.01 on June 16, 2026, as part of a planned sale.

Adaptive Biotechnologies Corporation Stock Down 15.9%

Shares of Adaptive Biotechnologies traded at $21.18 on Tuesday. The company boasts a market capitalization of roughly $3.35 billion. It has a forward P/E ratio of -82.9, indicating it is not yet profitable. The stock's beta of 2.15 suggests higher volatility compared to the market. Over the past year, the stock has seen a low of $9.96 and a high of $21.01, with a 50-day moving average of $15.32 and a 200-day moving average of $15.62.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors holds 29,993,708 shares valued at about $416.3 million, unchanged in their position. BlackRock reduced its stake by 30,534 shares, leaving it with 13,303,025 shares worth approximately $184.6 million, a slight 0.2% decrease. Vanguard Capital Management opened a new position with 6,094,144 shares valued at around $84.6 million. Westfield Capital Management increased its holdings by 1,376,237 shares, a 33.9% rise, totaling 5,436,718 shares valued at approximately $75.5 million.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its 'buy' rating for Adaptive Biotechnologies with a price target of $22. Other firms like Morgan Stanley and JP Morgan have also maintained their ratings, with targets of $18 and $19, respectively. The consensus among analysts is a 'strong buy', with an average target price of $20.29 based on seven opinions.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, based in Seattle, Washington, is a commercial-stage healthcare company. It specializes in developing an immune medicine platform aimed at diagnosing and treating various diseases. The company offers an immunosequencing platform that combines proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system. Its products are used in life sciences research, clinical diagnostics, and drug discovery applications.

Bottom Line

Insider transactions like those by Michelle Renee Griffin provide insight into the confidence of those closest to the company's operations. While these sales are informative, they do not necessarily indicate future performance. Investors often track these moves to gauge sentiment within the company. As always, it's crucial to remember that 13F filings and insider reports are historical and may not reflect current positions.